---
title: "Heron Therapeutics Faces Nasdaq Delisting Risk as Share Price Falls Below $1 Threshold"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295515180.md"
description: "Heron Therapeutics (HRTX) faces Nasdaq delisting risk after its share price fell below the $1.00 minimum bid price for 30 consecutive days. Failure to regain compliance within 180 days could lead to delisting, potentially reducing liquidity and hindering capital access. Despite this risk, Wall Street maintains a Moderate Buy consensus on HRTX stock."
datetime: "2026-08-11T06:00:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295515180.md)
  - [en](https://longbridge.com/en/news/295515180.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295515180.md)
---

# Heron Therapeutics Faces Nasdaq Delisting Risk as Share Price Falls Below $1 Threshold

Heron Therapeutics Inc (HRTX) has disclosed a new risk, in the Share Price & Shareholder Rights category.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Heron Therapeutics Inc. faces a material risk related to its continued listing on the Nasdaq Capital Market after receiving notice that its shares traded below the $1.00 minimum bid price for 30 consecutive business days. Failure to regain compliance within the prescribed 180‑day periods could result in delisting, which may significantly reduce stock liquidity, constrain access to equity financing, and harm its market reputation.

The possibility of delisting may already weigh on investor sentiment, as uncertainty around compliance can pressure the share price and deter new institutional participation. In turn, diminished trading volume and coverage could impair Heron’s ability to raise capital on acceptable terms, potentially limiting flexibility to fund operations, advance its pipeline, or respond to competitive and regulatory challenges.

Overall, Wall Street has a Moderate Buy consensus rating on HRTX stock based on 1 Buy and 1 Hold.

To learn more about Heron Therapeutics Inc’s risk factors, click here.

### Related Stocks

- [HRTX.US](https://longbridge.com/en/quote/HRTX.US.md)

## Related News & Research

- [HRTX: Q2 2026 net revenue grew 9% sequentially, but full-year guidance was withdrawn amid legal uncertainty](https://longbridge.com/en/news/295405345.md)
- [Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook](https://longbridge.com/en/news/295404922.md)
- [Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday](https://longbridge.com/en/news/294710967.md)
- [Heron Therapeutics amends Hercules Capital credit facility, cuts principal by $13.5 million](https://longbridge.com/en/news/295403890.md)
- [Worried the S&P 500 Bull Run Is Getting Old? Top Strategist Says 3.8 Years Is No Reason to Sell: 'Usually Last Many, Many More Years'](https://longbridge.com/en/news/295404538.md)